Ubicación del inventario

New Jersey, USA
Czech Republic, EU
Mumbai, India

* Sujeto a disponibilidad

Documentation

Descargar MSDS

Descargar COA de muestra

Incluye: HPLC, MASS/LC-MS, RMN de 1H, FT-IR, potencia, informe de elucidación estructural (SER) y datos analíticos adicionales según el producto.

Asp(10)-Teriparatide

● En Stock

Número de catálogo:	VE0025127
N.º CAS:	N/A
Fórmula mol.::	C181H290N54O52S2
Peso mol.::	4118.8 g/mol

Solicitar cotización

Añadir a la lista de RFQ

Información adicional sobre el Asp(10)-Teriparatide

Fármaco de origen

Teriparatide

Nombre IUPAC

Leu-Asn-Ser-Met-Glu-Arg-Val-Glu-Trp-Leu-Arg-Lys-Lys-Leu-Gln-Asp-Val-His-Asn-Phe-OH

Sinónimos farmacopeicos

N/A

Otros sinónimos

N/A

SMILES

O=C([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC(CNC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](N)CO)=O)C(C)C)=O)CO)=O)CCC(O)=O)=O)[C@H](CC)C)=O)CCC(N)=O)=O)CC(C)C)=O)CCSC)=O)CC1=CNC=N1)=O)CC(O)=O)=O)CC(C)C)=O)=O)CCCCN)=O)CC2=CNC=N2)=O)CC(C)C)=O)CC(N)=O)=O)CO)=O)CCSC)=O)CCC(O)=O)=O)CCCNC(N)=N)=O)C(C)C)=O)CCC(O)=O)=O)CC3=CNC4=C3C=CC=C4)=O)CC(C)C)=O)CCCNC(N)=N)=O)CCCCN)=O)CCCCN)=O)CC(C)C)=O)CCC(N)=O)=O)CC(O)=O)=O)C(C)C)=O)CC5=CNC=N5)=O)CC(N)=O)=O)CC6=CC=CC=C6)O

InChI

InChI=1S/C181H290N54O52S2/c1-21-96(18)146(235-160(267)114(48-53-140(248)249)211-174(281)132(84-238)231-177(284)143(93(12)13)232-147(254)103(185)82-236)178(285)215-111(45-50-134(187)240)155(262)218-119(65-90(6)7)163(270)212-116(55-62-289-20)158(265)223-124(71-100-79-195-86-202-100)167(274)227-128(75-141(250)251)171(278)216-117(63-88(2)3)148(255)200-81-137(243)204-105(39-27-30-56-182)149(256)222-123(70-99-78-194-85-201-99)166(273)220-121(67-92(10)11)164(271)224-127(74-136(189)242)170(277)230-131(83-237)173(280)213-115(54-61-288-19)157(264)209-112(46-51-138(244)245)153(260)207-109(43-34-60-198-181(192)193)159(266)233-144(94(14)15)175(282)214-113(47-52-139(246)247)156(263)221-122(69-98-77-199-104-38-26-25-37-102(98)104)165(272)219-120(66-91(8)9)161(268)208-108(42-33-59-197-180(190)191)151(258)205-106(40-28-31-57-183)150(257)206-107(41-29-32-58-184)152(259)217-118(64-89(4)5)162(269)210-110(44-49-133(186)239)154(261)226-129(76-142(252)253)172(279)234-145(95(16)17)176(283)228-125(72-101-80-196-87-203-101)168(275)225-126(73-135(188)241)169(276)229-130(179(286)287)68-97-35-23-22-24-36-97/h22-26, 35-38, 77-80, 85-96, 103, 105-132, 143-146, 199, 236-238H, 21, 27-34, 39-76, 81-84, 182-185H2, 1-20H3, (H2, 186, 239)(H2, 187, 240)(H2, 188, 241)(H2, 189, 242)(H, 194, 201)(H, 195, 202)(H, 196, 203)(H, 200, 255)(H, 204, 243)(H, 205, 258)(H, 206, 257)(H, 207, 260)(H, 208, 268)(H, 209, 264)(H, 210, 269)(H, 211, 281)(H, 212, 270)(H, 213, 280)(H, 214, 282)(H, 215, 285)(H, 216, 278)(H, 217, 259)(H, 218, 262)(H, 219, 272)(H, 220, 273)(H, 221, 263)(H, 222, 256)(H, 223, 265)(H, 224, 271)(H, 225, 275)(H, 226, 261)(H, 227, 274)(H, 228, 283)(H, 229, 276)(H, 230, 277)(H, 231, 284)(H, 232, 254)(H, 233, 266)(H, 234, 279)(H, 235, 267)(H, 244, 245)(H, 246, 247)(H, 248, 249)(H, 250, 251)(H, 252, 253)(H, 286, 287)(H4, 190, 191, 197)(H4, 192, 193, 198)/t96-, 103-, 105-, 106-, 107-, 108-, 109-, 110-, 111-, 112-, 113-, 114-, 115-, 116-, 117-, 118-, 119-, 120-, 121-, 122-, 123-, 124-, 125-, 126-, 127-, 128-, 129-, 130-, 131-, 132-, 143-, 144-, 145-, 146-/m0/s1

Descripción

Asp(10)-Teriparatide impurity is a site-specific variant of teriparatide in which position 10 contains aspartic acid; it arises as a process-related or degradation product during synthesis | formulation | or storage. Due to its altered primary sequence | this impurity can affect peptide conformation | receptor-binding potency | stability profile | and immunogenic potential | making precise control critical. Analytical characterization is performed using orthogonal techniques such as reversed-phase HPLC | LC-MS/MS peptide mapping and UV and MS quantitation to establish identity | purity and degradation kinetics. Control strategies include optimized synthesis and purification | validated analytical methods and specification limits aligned with regulatory guidance for peptide therapeutics.